Clinical trials: Solid Tumor, completed
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Self-Administered Relaxing Acupressure to Reduce Fatigue in Adolescent and Young Adult Cancer Survivors
This clinical trial tests the feasibility of self-administered relaxing acupressure on fatigue in adolescent and young adult (AYA) cancer survivors.
- Trial name
- NCT06442891
- Testing
- Acupressure Therapy, Internet-Based Intervention, Interview
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Michigan Rogel Cancer Center
Advanced Solid Tumors
An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG1827 in subjects with Advanced Solid Tumors, refractory or resistant to standard therapy…
- Trial name
- CSG-1827-101 (NCT06076291)
- Testing
- SG1827
- Where
- 6 sites in China
- Volunteers
- 19 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Cancer, NSCLC
Study of the CD40 Agonistic Monoclonal Antibody APX005M
This study is a phase 1 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M in adults with solid tumors.
- Conditions
- Cancer, NSCLC, Melanoma, Urothelial Carcinoma
- Trial name
- NCT02482168
- Testing
- APX005M
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Apexigen America, Inc.
Neoplasm Metastasis
Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours
Phase I, open label, dual centre, dose finding study to evaluate the safety and tolerability of continuous twice daily oral dosing with AZD2281 when administered in combination with Bevacizumab 10mg/kg given every 2 weeks to…
- Trial name
- NCT00710268
- Testing
- AZD2281, Bevacizumab
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Solid Tumor Cancers, Lung Cancer
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
The purpose of this study is to find out what effects, a drug called ado-trastuzumab emtansine has on the patient and their cancer which is thought to be controlled by the abnormal HER2 gene.
- Conditions
- Solid Tumor Cancers, Lung Cancer, Bladder Cancer, Urinary Tract Cancers
- Trial name
- NCT02675829
- Testing
- ado-trastuzumab emtansine
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor, Non Small Cell Lung Cancer
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
This is a phase I/Ib, first-in-human (FIH), open-label, dose escalation and dose expansion study to evaluate the safety and tolerability, biological and clinical activities of GEN-001 in patients with locally advanced or…
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
- Trial name
- NCT04601402
- Testing
- GEN-001, Avelumab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Genome & Company
Neuroblastoma, Sarcoma
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Background: Pediatric solid tumors (Ewing's sarcoma, rhabdomyosarcoma, and neuroblastoma) are often difficult to cure with standard treatment.
- Conditions
- Neuroblastoma, Sarcoma, Rhabdomyosarcoma-Embryonal, Rhabdomyosarcoma- Alveolar
- Trial name
- NCT00923351
- Testing
- Tumor Purged/CD25 Depleted Lymphocytes, Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine, rhIL-7
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors Refractory To Standard Therapy, Neoplasms
Kanglaite Injection Phase I Study
The Kanglaite Injection (KLT)is a novel broad spectrum anti-cancer injection produced from traditional Chinese medicinal herbs (the Coix Seed).
- Trial name
- NCT00031031
- Testing
- Kanglaite Injection (KLT)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- KangLaiTe USA
Tumors
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
Inthis study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with gemcitabine to patients with solid tumours.
- Trial name
- NCT00372437
- Testing
- MGCD0103, Gemcitabine
- Where
- 8 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Mirati Therapeutics Inc.
Solid Tumors, Pain
Acupuncture for Treatment of Uncontrolled Pain: A Feasibility Study
The goal of this clinical research study is to learn if using acupuncture with or without electrical stimulation in cancer patients with high levels of pain can help to relieve the pain.
- Trial name
- NCT00487331
- Testing
- Acupuncture, Survey
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
Anti-EGFR Immunoliposomes in Solid Tumors
Background: Site-specific delivery of anti-cancer therapeutics is paramount for both reducing nonspecific toxicities and increasing efficacy of chemotherapeutic agents.
- Trial name
- NCT01702129
- Testing
- anti-EGFR immunoliposomes loaded with doxorubicin
- Where
- Switzerland
- Volunteers
- 26 people
- Sponsor
- University Hospital, Basel, Switzerland
Solid Tumors
Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors
Patients who had clinical benefit following a single infusion of CP-870, 893 on Protocol UPCC 10903 will receive a single repeated infusion of CP-870,893 at the same dose given on UPCC 10903 intravenously.
- Trial name
- NCT02157831
- Testing
- CP-870,893
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cancer, Advanced Solid Malignancies
Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects
The primary purpose of this study is to explore the safety and tolerability of MEDI-573 in Japanese subjects with advanced solid tumours refractory to standard therapy or for which no standard therapy exists.
- Trial name
- NCT01340040
- Testing
- MEDI-573
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Malignant Solid Tumors
First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
This is the first-in-human study of 68Ga/64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.
- Trial name
- NCT05814835
- Testing
- 2-4 mCi 68Ga/64Cu-FAPI-XT117, 4-6 mCi 68Ga/64Cu-FAPI-XT117, 6-8 mCi 68Ga/64Cu-FAPI-XT117
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Chinese PLA General Hospital
Tumor, Solid
Varian ProBeam Proton Therapy System China Clinical Trial (Hefei)
This study is prospective, two-center, single-arm objective performance criteria. This trial will be conducted in 2 clinical trial sites with a total of 47 subjects enrolled.
- Trial name
- ProBeam (NCT05463055)
- Testing
- Proton Therapy System (ProBeam)
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Varian, a Siemens Healthineers Company
Solid Tumor
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
The purpose of this study is to evaluate the safety and effectiveness of Nivolumab in combination with Ipilimumab in Chinese participants with previously treated late stage cancer.
- Trial name
- NCT03195478
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in China
- Volunteers
- 37 people
- Sponsor
- Bristol-Myers Squibb
Lymphomas, Tumors
Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan, with weekly vincristine, temozolomide and vantin; to evaluate the feasibility of repetitive cycles of this chemotherapy and to estimate the…
- Trial name
- NCT00222443
- Testing
- Irinotecan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Oklahoma
Tumor, Solid
Varian ProBeam Proton Therapy System Clinical Trial (Shandong)
This study is prospective, single-center, single-arm objective performance criteria. This trial will be conducted with a total of 47 subjects enrolled.
- Trial name
- NCT06340815
- Testing
- Radiation: Proton Therapy System (ProBeam)
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Varian, a Siemens Healthineers Company
Solid Tumours
Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden
Introduction: Many reimbursement authorities use economic evaluation to help guide decisions regarding the adoption of new treatments in reimbursement systems.
- Trial name
- NCT01209091
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neoplasms
Relative Bioavailability of Pimasertib in Cancer Patients
This is a Phase 1, multi-center, open-label, single-dose, 2 period, 2 sequence cross-over trial to investigate the relative bioavailability of 2 solid oral pimasertib formulations in cancer subjects (Part A), followed by…
- Trial name
- NCT01992874
- Testing
- Pimasertib Capsule (Part A), Pimasertib Tablet (Part A), Pimasertib Capsule (Part B and trial extension phase)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- EMD Serono
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.